Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Dr. Sharon O'Toole

Snr Experimental Officer (Obstetrics)
TRINITY CENTRE, S J H

Senior Research Fellow (Histopathology)


Sharon O'Toole obtained a BSc Hons in UCG in 1994 and received an award for outstanding results. She went on to receive one of the limited places on the MSc Biotechnology course and graduated in 1996. From there she worked as a QC analyst in Schering Plough. She was then selected to assist one of the leading members of the technical transfer team who was involved in the transfer of technology from the US. An opportunity then arose in TCD, which would eventually lead to a PhD. She received the O'Meara scholarship from Trinity. She has gained enormous experience in the area of ovarian cancer and has played a major role in the development of studies in gynaecological cancer. During the course of her PhD she showed innovative skills in developing assay systems for chemosensitivity/resistance testing. Sharon forged many links with industry and became principal investigator on a study funded by Bristol Myers Squibb. She has worked directly with Applied Biosystems and presented for them at symposiums. Other funding she received for studies included the royal city of Dublin hospital trust fund and the HRB. She then became a coinvestigator on a 5th framework study funded by the European commission with a consortium of eight centres throughout Europe. She has presented at both national and international conferences and published in peer-reviewed journals. She was nominated to present at the Blair Bell symposium in London. She received an award from the International society for preventive oncology for her presentation in Geneva
  Gynaecology oncology   Obstetrics/Gynecology   Oestregens in age related urogenital diseases
 Identification of novel biomarkers in recurrent/chemoresistant ovarian cancer
 A Consortium of researchers dedicated to understanding and treatment of ovarian cancer: The DISCOVARY Consortium
 Ageing and the Urogenital Tract
 Chemosensitivity testing in gynaecological cancers

Language Skill Reading Skill Writing Skill Speaking
English Fluent Fluent Fluent
French Fluent Medium Medium
Details Date From Date To
Member of European Association for Cancer Research. Member of Irish Association for Cancer Research
Martin CM, Astbury K, Kehoe L, O'Crowley JB, O'Toole S, O'Leary JJ. , The Use of MYBL2 as a Novel Candidate Biomarker of Cervical Cancer. , Methods Mol Biol, 1249, 2015, p241 - 251, Journal Article, PUBLISHED
Langhe R, Norris L, Saadeh FA, Blackshields G, Varley R, Harrison A, Gleeson N, Spillane C, Martin C, O'Donnell DM, D'Arcy T, O'Leary J, O'Toole S, A novel serum microRNA panel to discriminate benign from malignant ovarian disease, Cancer Letters, 356, ((2ptB)), 2015, p628-636-, Journal Article, PUBLISHED  DOI
Steven Busschotsa, b, , Sharon O'Tooleb, , John J. O'Learya, b, , Britta Stordala, c, , , Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells, Experimental Cell Research, 2015, Journal Article, IN_PRESS  TARA - Full Text  DOI
Noninvasive Biomarkers in Ovarian Cancer in, editor(s)Debmalya Barh, Angelo Carpi, Mukesh Verma, Mehmet Gunduz , Cancer Biomarkers: Minimal and Noninvasive Early Diagnosis and Prognosis , CRC press, 2014, [O'Toole, SA, Ancuta, E, Langhe, R, Cahill, DJ, Murphy, M, Martin, C, McEvoy, L, Spillane, C, Sheils, O, Petricoin, E, Liotta, L, O'Leary JJ], Book Chapter, PUBLISHED
Keegan, Helen Pilkington, Loretto McInerney, Jamie Jeney, Csaba Benczik, Márta Cleary, Sinead von Bunau, Gunther Turner, Michael D'Arcy, Tom O' Toole, Sharon Borbála, Pal-Szenthe Borbála, Kaltenecker Johanna, Mózes Anettc, Kovács Agnes, Solt Bolger, Noel O'Leary, John Martin, Cara, Human papillomavirus detection and genotyping, by HC2, Full-Spectrum HPV and Molecular Beacon Real-Time HPV assay in an Irish colposcopy clinic, Journal of Virological Methods, 2014, Journal Article, PUBLISHED  TARA - Full Text
d'Adhemar CJ, Spillane CD, Gallagher MF, Bates M, Costello KM, Barry-O'Crowley J, Haley K, Kernan N, Murphy C, Smyth PC, O'Byrne K, Pennington S, Cooke AA, Ffrench B, Martin CM, O'Donnell D, Hennessy B, Stordal B, Finn S, McCann A, Gleeson N, D'Arcy T, Flood B, O'Neill LA, Sheils O, O'Toole S, O'Leary JJ., The MyD88+ Phenotype Is an Adverse Prognostic Factor in Epithelial Ovarian Cancer., PLoS One. , 9, (6), 2014, pe100816-, Journal Article, PUBLISHED  TARA - Full Text  DOI
Laios A, Mohamed BM, Kelly L, Flavin R, Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, Davies A, Lawson M, Gleeson N, D'Arcy T, d'Adhemar C, Norris L, Langhe R, Saadeh FA, O'Leary JJ, O'Toole SA, Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening., International journal of molecular sciences, 14, (1), 2013, p2085-103 , Journal Article, PUBLISHED  TARA - Full Text
Abu Saadeh F, Norris L, O'Toole S, Gleeson N, Venous thromboembolism in ovarian cancer: Incidence, risk factors and impact on survival., European Journal of Obstetrics & Gynecology and Reproductive Biology , 170, (1), 2013, p214 - 218, Journal Article, PUBLISHED  Other
Abu Saadeh, Norris L, O'Toole S, Mohamed BM, Langhe R, O'Leary J, Gleeson N, Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk., Thrombosis Research, 132, 2013, p627 - 634, Journal Article, PUBLISHED  DOI
White C, Keegan H, Pilkington L, Ruttle C, Kerr P, Sharp L, O'Toole S, Turner M, Prendiville W, D'Arcy T, Fitzpatrick M, Lenehan P, Flannelly G, O'Leary JJ, Martin CM, Evaluation of the clinical performance of the cobas 4800 HPV test in patients referred for colposcopy., Journal of clinical microbiology, 51, (10), 2013, p3415-7 , Journal Article, PUBLISHED  TARA - Full Text
  

Page 1 of 3
Abu Saadeh F, O'Toole S, Gleeson N, Norris L, Peak ant-Xa levels following LMWH (tinzaparin) prophylaxis in gynaecological cancer patients post surgery, Thrombosis Research, 7th Internation Conference on Thrombosis & Hemostatis Issues in Cancer, , Bergamot Italy, May 2014, edited by A Falanga, B. Brenner, F, Rickles , 133, (Suppl 2), Elsevier, 2014, Meeting Abstract, PUBLISHED
Ibrahim N, Norris L, O'Toole S, McHugh T, Gleeson N, Does extended thromboprophylaxis help reduce the incidence of venous thromboembolism in gynaecological cancer patients?, Thrombosis Research, 7th Internation Conference onal Thrombosis & Hemostatis Issues in Cancer,, Bergamo Italy, May 2014, edited by A Falanga, B. Brenner, F, Rickles , 133, (Suppl 2), Elsevier, 2014, Published Abstract, PUBLISHED
Abu Saadeh. F, Norris. L, O' Toole, Gleeson. N., Assessing the risk and mortality of venous thromboembolism in ovarian cancer., International Journal of Gynecological Cancer, 14th Biennial Meeting of the International Gynecological Cancer Society., Vancouver, Canada, October 2012, 22, (Suppl 3), 2012, Meeting Abstract, PUBLISHED
Abu Saadeh F, Norris L, O'Toole S, Langhe R, O'Leary JJ, Gleeson N., Does tissue factor and tissue factor pathway inhibitor over-expression play a role in the development of venous thromboembolism in ovarian cancer patients?, Thrombosis Research, 6th International Conference on Thrombosis & Hemostasis Issues in Cancer, Bergamo Italy, April 2012, edited by A Falanga, B. Brenner, F, Rickles , 129, ((Suppl 1)), Elsevier, 2012, Published Abstract, PUBLISHED
Abu Saadeh. F, Norris. L, O' Toole. S, Langhe. R, O' Leary. J, Gleeson. N. , Why is venous thromboembolism is a common complication of ovarian cancer? , International Journal of Gynecological Cancer , 14th Biennial Meeting of the International Gynecological Cancer Society. , Vancouver, Canada, October 2012, 22, (Suppl 3), 2012, Published Abstract, PUBLISHED
Abu Saadeh F, Norris L, O'Toole S, Langhe R, Gleeson N., Procoagulant activity in patients with gynecological malignancies and the effect of neoadjuvant chemotherapy , Thrombosis Research, 6th International Conference on Thrombosis & Hemostasis Issues in Cancer, Bergamo Italy, April 2012, edited by A Falanga, B. Brenner, F, Rickles , 129, (Suppl 1), Elsevier, 2012, Published Abstract, PUBLISHED
Abu Saadeh. F, Norris. L, O' Toole. S, Langhe. R, Gleeson. N, Endogenous thrombin potential as a marker for venous thrombosis in ovarian cancer., International Journal of Gynecological Cancer , 14th Biennial Meeting of the International Gynecological Cancer Society., Vancouver, Canada, October 2012, 22, (Suppl 3), 2012, Published Abstract, PUBLISHED
Abu Saadeh. F, Norris. L, O' Toole. S, Langhe. R, Gleeson. N., ETP as a marker for venous thromboembolism in gynaecologial cancer patients post surgery, International Journal of Gynecological Cancer, 14th Biennial Meeting of the International Gynecological Cancer Society., Vancouver, Canada, October 2012, 22, (Suppl 3), 2012, Published Abstract, PUBLISHED
SA O'Toole, A Laios, BL Sheppard, NC Gleeson, T D'Arcy, EPJ McGuinness, J Bonnar, O Sheils and JJ O'Leary. , Potential predictors of chemotherapy response in ovarian cancer how do we define chemosensitivity?, Laboratory Investigation, United States and Canadian Society of Pathology, Atlanta, USA, Feb 2006, 86, (Suppl 1), Nature, 2006, pp190A , Meeting Abstract, PUBLISHED
A Laios, SA O'Toole, BL Sheppard, NC Gleeson, T D'Arcy, E PJ McGuinness, M Ring, O Sheils and JJ O'Leary, Molecular profiling of primary versus recurrent ovarian serous papillary adenocarcinomas. , Laboratory Investigation, United States and Canadian Society of Pathology, Atlanta, USA, Feb 2006, 86, (Suppl 1), Nature, 2006, pp185A , Meeting Abstract, PUBLISHED

  

Page 1 of 4
-Early diagnostics in ovarian cancer -Chemoresistance in ovarian cancer Chemosensitivity/Resistance testing of malignant gynaecological tumours -Examination of Fibrinolytic systems of malignant gynaecological tumours -Examination of angiogenesis in ovarian cancers. -Examination of multidrug resistance genes in gynaecological tumours. -Estrogen regulated genes in endometrial cancer. -PhytoSERMs and Endometrial Cancer